Evaluation of a New Formula for Calculating Heparin Dose for Cardiopulmonary Bypass Patients


Introduction: Anticoagulation is essential during CPB in cardiac surgery. It is generally performed using heparin; however the widely used formula for its dosing is based solely on body weight. Although the formula assumes activated clotting time (ACT) to be within normal range, baseline ACT varies in each patient. Thus, we developed an original formula, which takes into account baseline ACT in addition to body weight to calculate a more proper dose for initial administration of heparin. In this study, we monitored the ACT to examine if the dose of heparin calculated using our formula can prolong the ACT to the target range, and we determined the factors which interfere with the prolongation of ACT. Methods: Between October 2010 and April 2011, 141 consecutive patients underwent cardiac surgery requiring cardiopulmonary bypass at our hospital. We measured ACT 3 minutes after the initial administration of heparin and considered ACT values >400 seconds as appropriate for safe initiation of CPB. Results: Using the proposed formula, administered heparin dose was 241 ± 27 IU/kg and target ACT was achieved in 86.4% of patients. Multivariate analysis was performed to determine the effect of patient background factors on target ACT achievement. Body weight, age, and preoperative heparin therapy, which showed significant differences, were further analyzed. Conclusions: This study demonstrated that our newly developed formula could be used to properly calculate the optimal initial dose of heparin.

Share and Cite:

Nakasuji, A. , Matsushita, S. , Inaba, H. , Yamamoto, T. , Kuwaki, K. , Inada, E. and Amano, A. (2014) Evaluation of a New Formula for Calculating Heparin Dose for Cardiopulmonary Bypass Patients. Open Journal of Thoracic Surgery, 4, 32-38. doi: 10.4236/ojts.2014.42008.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Gibbon, J.H. and Passim, J.R. (1954) Application of a Mechanical Heart and Lung Apparatus to Cardiac Surgery. Minnesota Medicine, 37, 171-185.
[2] Bull, B.S., Karpman, R.A., Huse, W.M. and Briggs, B.D. (1975) Heparin Therapy during Extracorporeal Circulation. Problems Inherent in Existing Heparin Protocols. The Journal of Thoracic and Cardiovascular Surgery, 69, 674-684.
[3] Bull, B.S., Huse, W.M., Brauer, F.S. and Korpman, R.A. (1975) Heparin Therapy during Extracorporeal Circulation. II. The Use of a Dose-Response Curve to Individualize Heparin and Protamine Dosage. The Journal of Thoracic and Cardiovascular Surgery, 69, 685-689.
[4] Shuhaibar, M.N., Hargrove, M., Millat, M.H., O’Donnell, A. and Aherne, T. (2004) How Much Heparin Do We Really Need to Go on Pump? A Rethink of Current Practices. European Journal Cardio-Thoracic Surgery, 26, 947-950.
[5] Fromes, Y., Daghildjian, K., Caumartin, L., Fischer, M., Rouquette, I., Deleuze, P., et al. (2011) A Comparison of Low vs Conventional-Dose Heparin for Minimal Cardiopulmonary Bypass in Coronary Artery Bypass Grafting Surgery. Anaesthesia, 66, 488-492.
[6] Gravlee, G.P., Rogers, A.T., Dudas, L.M.R.N., Taylor, R., et al. (1992) Heparin Management Protocol for Cardiopulmonary Bypass Influences Postoperative Heparin Rebound but Not Bleeding. Anesthesiology, 76, 93-401.
[7] John, L.C., Rees, G.M. and Kovacs, I.B. (1993) Inhibition of Platelet Function by Heparin. An Etiologic Factor in Post Bypass Hemorrhage. The Journal of Thoracic and Cardiovascular Surgery, 105, 816-822.
[8] Purandare, S.V., Parulkar, G.B., Panday, S.R., Bhattacharya, S. and Bhatt, M.M. (1979) Heparin Rebound a Cause of Bleeding Following Open Heart Surgery. Journal of Postgraduate Medicine, 25, 70-74.
[9] Teoh, K.H.T., Young, E., Blackall, M.H., Roberts, R.S. and Hirsh, J. (2004) Can Extra Protamine Eliminate Heparin Rebound Following Cardiopulmonary Bypass Surgery? The Journal of Thoracic and Cardiovascular Surgery, 128, 211-219.
[10] Ravi, T. and Chenq, D.C. (2006) Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures. Anesthesia & Analgesia, 103, 1370-1372.
[11] Brinks, H.J., Weerwind, P.W., Bogdan, S., Verbruggen, H. and Brouwer, M.H. (2001) Does Heparin Pretreatment Affect the Haemostatic System during and after Cardiopulmonary Bypass? Perfusion, 16, 3-12.
[12] Staples, M.H., Dunton, R.F., Karlson, K.J., Leonardi, H.K. and Berger, R.L. (1994) Heparin Resistance after Preoperative Heparin Therapy or Intraaortic Balloon Pumping. The Annals of Thoracic Surgery, 57, 1211-1216.
[13] Sagripanti, A. and Carpi, A. (1998) Natural Anticoagulants, Aging, and Thromboembolism. Experimental Gerontology, 33, 891-896.
[14] Williams, M.R., D’Ambra, A.B., Beck, J.R., et al. (2000) A Randomized Trial of Antithrombin Concentrate for Treatment of Heparin Resistance. The Annals of Thoracic Surgery, 70, 873-877.
[15] Ranucci, M., Isgrò, G., Cazzaniga, A., Ditta, A., Boncilli, A., Cotza, M., et al. (2002) Different Patterns of Heparin Resistance: Therapeutic Implications. Perfusion, 17, 199-204.
[16] Ranucci, M., Isgrò, G., Cazzaniga, A., Soro, G., Menicanti, L. and Frigiola, A. (1999) Predictors for Heparin Resistance in Patients Undergoing Coronary Artery Bypass Grafting. Perfusion, 14, 437-442.
[17] Demma, L.J., Winkler, A.M. and Levy, J.H. (2011) FAHA. A Diagnosis of Heparin-Induced Thrombocytopenia with Combined Clinical and Laboratory Methods in Cardiothoracic Surgical Intensive Care Unit Patients. Anesthesia & Analgesia, 113, 697-702.
[18] O’Donnell, J., Tuddenham, E.G., Manning, R., Kemball-Cook, G., Johnson, D. and Laffan, M. (1997) High Prevalence of Elevated Factor VIII Levels in Patients Referred for Thrombophilia Screening: Role of Increased Synthesis and Relationship to the Acute Phase Reaction. Thrombosis and Haemostasis, 77, 825-828.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.